Sanofi Pasteur news from FierceBiotech

Score one win for Ontario province in the field of economic development. Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, will build a C$100 million R&D facility in Toronto with the province Read more...

Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Maxygen stands to gain up to $24.5 million in the deal. The Read more...

> Bristol-Myers Squibb has returned the rights to vinflunine to Pierre Fabre. The therapy was studied as a treatment for bladder cancer. Read more...

Sanofi Pasteur is buying into Acambis' program for a novel West Nile vaccine. Read more...

Press Release: FDA Advisory Committee Recommends Licensure Of New Pediatric Combination Vaccine

Read more...

An expert panel for the FDA has concluded that Pentacel, a five-in-one vaccine made by Sanofi-Pasteur, is safe and effective. The injection is designed to prevent diphtheria, tetanus, whooping cough, polio and bacterial infection caused by Haemophilus influenzae Type B. The group did recommend follow-up studies in the event that the FDA formally approves the jab. The vaccine could replace seven of the 23 injections received by children.

- see this …

Read more...

The Department of Health and Human Services has awarded a total of $199.45 million to three vaccine makers in order to stockpile 5.3 million additional doses of H5N1 vaccine. The bulk of the money--$117.9 million--has been awarded to Sanofi Pasteur for 3.7 million doses of the drug. Novartis has received $40.95 million for 800,000 doses and GSK also garnered $40.6 million for 800,000 doses. "These newest vaccine purchases supplement the existing stockpile of 5.9 million doses of H5N1 …

Read more...

Press Release: HHS Buys Additional Vaccine for Potential Use in an Influenza Pandemic

Read more...

Sanofi Pasteur says that its experimental bird flu vaccine has proved effective against recent variations of the virus, leading its researchers believe that the therapy could be effective against a viral mutation that could trigger a human pandemic. Sanofi researchers announced last May that the vaccine appeared safe and effective in early human trials. And the new data indicates that the vaccine produces antibodies that work against recently discovered strains of H5N1.

- here's the AFX report on the vaccine

The FDA has signed off on the flu vaccines to be made for the upcoming season by GlaxoSmithKline, Chiron, MedImmune and Sanofi-Pasteur. Those four manufacturers are intended to supply 100 million doses of vaccine to the U.S. market, which is expected to be enough to satisfy demand. Federal officials have been working hard to try to even out the kinks in the supply of flu vaccines to the country, working to prevent the kind of supply snafus that have snarled treatment programs over recent …

Read more...